Wall Street closes at a record for the first time since end of January
Investing.com - Needham reiterated a Buy rating on RxSight Inc. (NASDAQ:RXST) and maintained its $13.00 price target on the stock.
The firm noted that RxSight’s fourth-quarter 2025 revenue aligned with its preannouncement. Financial guidance missed consensus estimates at the mid-points.
Needham stated that assumptions underlying the company’s guidance appear reasonable and could translate into growth recovering throughout the year. The firm highlighted that commercial initiatives continue to progress, with management pointing to early successes.
The research firm said the guidance appears achievable. Needham cited an undemanding valuation as a factor supporting its rating. The stock currently trades at $8.81, well below Needham’s $13 target and InvestingPro’s Fair Value of $10.90, suggesting the company is undervalued. The shares have declined nearly 70% over the past year, contributing to the attractive valuation picture.
The firm maintained its Buy rating on RxSight shares based on these factors. InvestingPro subscribers have access to 5 additional exclusive tips for RXST, plus comprehensive Pro Research Reports covering over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, RxSight Inc. reported its fourth-quarter 2025 earnings, which exceeded expectations. The company announced an adjusted earnings per share (EPS) of $0.03, outperforming the forecasted loss of $0.35. Additionally, RxSight’s revenue for the quarter reached $32.6 million, surpassing the anticipated $28.1 million. These results highlight the company’s strong financial performance in the recent period. Despite these positive earnings and revenue figures, the stock showed a slight decline in regular trading hours, although it experienced a minor increase in after-hours trading. Investors and analysts may find these developments noteworthy as they assess the company’s financial health and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.